Divi's Laboratories Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹7247.50
Market cap
1,92,368 Cr
Stock P/E
70.9
P/B
11.48
Dividend yield
0.4%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,778 Cr | 1,909 Cr | 1,855 Cr | 2,303 Cr | 2,118 Cr | 2,338 Cr | 2,319 Cr | 2,585 Cr | 2,410 Cr | 2,715 Cr | 2,604 Cr | 2,831 Cr |
| Operating expenses (approx.) | 1,274 Cr | 1,430 Cr | 1,366 Cr | 1,572 Cr | 1,496 Cr | 1,622 Cr | 1,576 Cr | 1,699 Cr | 1,681 Cr | 1,827 Cr | 1,714 Cr | 1,897 Cr |
| EBITDA | 504 Cr | 479 Cr | 489 Cr | 731 Cr | 622 Cr | 716 Cr | 743 Cr | 886 Cr | 729 Cr | 888 Cr | 890 Cr | 934 Cr |
| OPM % | 28.3% | 25.1% | 26.4% | 31.7% | 29.4% | 30.6% | 32.0% | 34.3% | 30.2% | 32.7% | 34.2% | 33.0% |
| Other income | 81 Cr | 86 Cr | 95 Cr | 79 Cr | 79 Cr | 106 Cr | 82 Cr | 86 Cr | 119 Cr | 145 Cr | 88 Cr | 155 Cr |
| Interest | 0.0000 Cr | 1 Cr | 0.0000 Cr | 2 Cr | 0.0000 Cr | 1 Cr | 0.0000 Cr | 1 Cr | 3 Cr | 8 Cr | 6 Cr | 6 Cr |
| Depreciation | 93 Cr | 95 Cr | 95 Cr | 95 Cr | 97 Cr | 99 Cr | 99 Cr | 107 Cr | 112 Cr | 113 Cr | 118 Cr | 120 Cr |
| Profit before tax | 492 Cr | 469 Cr | 489 Cr | 713 Cr | 604 Cr | 722 Cr | 726 Cr | 864 Cr | 733 Cr | 912 Cr | 780 Cr | 963 Cr |
| Tax % | 27.6% | 25.8% | 26.8% | 24.5% | 28.8% | 29.4% | 18.9% | 23.4% | 25.6% | 24.5% | 25.3% | 22.0% |
| Net profit | 356 Cr | 348 Cr | 358 Cr | 538 Cr | 430 Cr | 510 Cr | 589 Cr | 662 Cr | 545 Cr | 689 Cr | 583 Cr | 751 Cr |
| EPS (₹) | ₹13.41 | ₹13.11 | ₹13.50 | ₹20.25 | ₹16.20 | ₹19.20 | ₹22.20 | ₹24.93 | ₹20.49 | ₹25.97 | ₹21.98 | ₹28.31 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,946 Cr | 5,394 Cr | 6,969 Cr | 8,960 Cr | 7,768 Cr | 7,845 Cr | 9,360 Cr | 10,560 Cr | Sign in for TTM |
| Operating expenses (approx.) | 3,074 Cr | 3,572 Cr | 4,109 Cr | 5,078 Cr | 5,400 Cr | 5,640 Cr | 6,392 Cr | 7,119 Cr | Sign in for TTM |
| EBITDA | 1,872 Cr | 1,822 Cr | 2,860 Cr | 3,882 Cr | 2,368 Cr | 2,205 Cr | 2,968 Cr | 3,441 Cr | Sign in for TTM |
| OPM % | 37.8% | 33.8% | 41.0% | 43.3% | 30.5% | 28.1% | 31.7% | 32.6% | Sign in for TTM |
| Other income | 156 Cr | 190 Cr | 63 Cr | 114 Cr | 345 Cr | 339 Cr | 352 Cr | 507 Cr | Sign in for TTM |
| Interest | 4 Cr | 6 Cr | 0.87 Cr | 0.80 Cr | 0.67 Cr | 3 Cr | 2 Cr | 23 Cr | Sign in for TTM |
| Depreciation | 169 Cr | 186 Cr | 256 Cr | 312 Cr | 343 Cr | 378 Cr | 402 Cr | 463 Cr | Sign in for TTM |
| Profit before tax | 1,855 Cr | 1,819 Cr | 2,666 Cr | 3,684 Cr | 2,369 Cr | 2,163 Cr | 2,916 Cr | 3,388 Cr | Sign in for TTM |
| Tax % | 27.1% | 24.3% | 25.6% | 19.6% | 23.0% | 26.0% | 24.9% | 24.2% | Sign in for TTM |
| Net profit | 1,353 Cr | 1,377 Cr | 1,984 Cr | 2,960 Cr | 1,823 Cr | 1,600 Cr | 2,191 Cr | 2,568 Cr | Sign in for TTM |
| EPS (₹) | ₹50.96 | ₹51.85 | ₹74.75 | ₹111.52 | ₹68.69 | ₹60.27 | ₹82.53 | ₹96.75 | Sign in for TTM |
| Dividend payout % | — | — | — | 17.9% | 43.7% | 49.8% | 36.3% | 31.0% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 53 Cr | 53 Cr | 53 Cr | 53 Cr | 53 Cr | 53 Cr | 53 Cr | 53 Cr |
| Reserves | 6,904 Cr | 7,257 Cr | 9,242 Cr | 11,675 Cr | 12,714 Cr | 13,518 Cr | 14,916 Cr | 16,708 Cr |
| Borrowings | — | — | — | — | — | — | 2 Cr | — |
| Other liabilities | — | — | — | — | 1,672 Cr | 1,899 Cr | 1,961 Cr | 3,272 Cr |
| Total liabilities | — | — | — | — | 14,439 Cr | 15,470 Cr | 16,932 Cr | 20,033 Cr |
| Fixed assets (net) | — | — | — | — | 4,714 Cr | 4,733 Cr | 5,437 Cr | 6,515 Cr |
| CWIP | — | — | — | — | 212 Cr | 778 Cr | 1,022 Cr | 2,113 Cr |
| Investments | — | — | — | — | 77 Cr | 82 Cr | 65 Cr | 69 Cr |
| Other assets | — | — | — | — | 9,312 Cr | 9,675 Cr | 10,081 Cr | 11,096 Cr |
| Total assets | — | — | — | — | 14,439 Cr | 15,470 Cr | 16,932 Cr | 20,033 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 1,912 Cr | 2,460 Cr | 1,261 Cr | 1,653 Cr | 2,738 Cr |
| Cash from investing | — | — | — | -2,195 Cr | -2,708 Cr | -269 Cr | -804 Cr | -2,219 Cr |
| Cash from financing | — | — | — | -532 Cr | -797 Cr | -799 Cr | -799 Cr | -804 Cr |
| Net cash flow | — | — | — | -816 Cr | -1,045 Cr | 193 Cr | 50 Cr | -285 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 1,199 Cr | 1,987 Cr | 258 Cr | 215 Cr | 218 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 24.5% | 22.4% | 28.0% | 30.4% | 15.9% | 13.5% | 17.1% | 17.8% |
| ROE % | 0.0% | 18.8% | 21.3% | 25.2% | 14.3% | 11.8% | 14.6% | 15.3% |
| Debtor days | — | — | — | — | 84 | 100 | 106 | 103 |
| Inventory days | — | — | — | — | 363 | 360 | 308 | 329 |
| Days payable | — | — | — | — | 92 | 93 | 87 | 101 |
| Cash conversion cycle | — | — | — | — | 355 | 367 | 328 | 331 |
| Debt / equity | — | — | — | — | — | — | 0.0001 | — |
| Current ratio | — | — | — | — | 8.46 | 7.57 | 6.94 | 5.43 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -0.07 | -0.16 | -0.14 | -0.04 |
Compare with peers
Loading peers…